It revolves around four points: target-site arrival (does the drug enter the tissue it should), non-target deposition (abnormal enrichment in non-target tissues such as heart, kidney, liver), barrier penetration (can it cross blood-brain, placental barriers), and metabolite distribution (do parent drug and metabolites co-localize). The in-situ nature of MSI allows these questions, originally needing multiple ex-vivo experiments, to be directly answered with molecular images on the same section.
The Neo-Source MSI DPI lists pharmacokinetics as a key area: used for new drug R&D, distribution studies of drugs and metabolites in different organs at different times, drug quantification and drug discovery; its matrix-free, low-ion-suppression design and ability to analyze complex samples directly make it compatible with Agilent, AB SCIEX and Thermo instruments.
Drug distribution is dynamic. Sampling and imaging at different time points after administration can reconstruct the 'entry–enrichment–clearance' curve of compounds in the body; sections from multiple time points and multiple organs (liver, kidney, brain, intestine, tumor, etc.) placed side by side depict a complete spatiotemporal distribution.
In the DPI case, tests on animal tissues and plant leaves showed that, in both positive and negative ion modes compared with traditional DESI, more than a hundred additional secondary metabolites could be detected, with overall signal enhanced by 1–3 orders of magnitude; this sensitivity advantage also benefits multi-time-point spatial tracking of low-abundance drugs and metabolites.
Abnormal drug distribution often precedes visible pathological changes. If MSI finds abnormal drug enrichment in non-target organs, it can serve as an early hint of potential toxicity, guiding dose optimization and formulation improvement. Registering the distribution map with adjacent H&E sections can also precisely overlay molecular signals onto damaged tissue structures.
The engineering value of matrix-free preparation is highlighted here: the two Neo-Source imaging sources are matrix-free and measure on demand, reducing sample handling from 'half a day at best' to 'measure on demand', significantly accelerating safety evaluation requiring many time points and dose groups.
MSI gives relative spatial distribution and ion-intensity images; quantification requires standard curves or internal standards, considering histology and dosing regimen. It excels at localization and discovery; the gold standard for absolute quantification is still often complemented by LC-MS.
In engineering deployment, the two Neo-Source imaging sources are compatible with mainstream mass spectrometers and provide a self-developed titanium-alloy ion transfer tube that does not damage the sample at the front end and is detachable for cleaning, enabling drug distribution imaging to move stably and reproducibly from research projects into quality-control and screening production lines.
To obtain detailed specifications, compatible models, or a quotation for the MSI LDPI / DPI full series imaging ion sources, visit the Neo-Source official website, or contact the official team for compatibility advice tailored to your mass spectrometer (Agilent / SCIEX / Thermo and other mainstream MS).